Lonza Group Investor Presentation — October 2018

Document content

Q3 2018 Qualitative Business Update

Lonza Continues Strong Momentum in Businesses

Along the Healthcare Continuum in Q3 2018 and

Confirms Positive Outlook for the Full Year

Richard Ridinger –CEO

Q3 2018 Qualitative Business Update I 25 October 2018 Agenda

Q3 2018 Qualitative Business Update Summary

Specialty Ingredients

Outlook 2018 and Mid -Term Guidance 2022

Q3 2018 Qualitative Business Update I 25 October 2018

2Businesses in Pharma & Biotech and in Consumer Health –including

capsule and combined ingredient and dosage form offerings –continued

Announcement of Ibex™ Solutions expansion with new, innovative drug

substance and drug product offerings from preclinical to commercial –

including fill & finish services –was well received

A challenging environment for cyclical businesses in mature parts of the

portfolio continued to have an impact on Consumer & Resources

Protection; specialty composites portfolio sustained robust performance

Outlook for the full year, which was upgraded with Half-Year 2018 results,

Capital Markets Day in September provided strategy update for continued

growth toward achieving Lonza’s Mid-Term Guidance 2022 and beyond

Q3 2018 Qualitative Business Update I 25 October 2018 Q3 2018 Qualitative Business Update Summary

Ongoing strong momentum for all businesses along the healthcare continuum

Q3 2018 Qualitative Business Update Summary

Specialty Ingredients

Outlook 2018 and Mid -Term Guidance 2022

Q3 2018 Qualitative Business Update I 25 October 2018

4Ibex™ Solutions in Visp (CH) –Expansion with New, Innovative Offerings

Ibex™ Design and Ibex™ Develop with offerings from preclinical through to commercialization –now also including fill & finish

Q3 2018 Qualitative Business Update I 25 October 2018

Preview truncated — download the full document for the complete content.